promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein

selectively expressed in acute promyelocytic leukemia cells; recognized by T lymphocytes; amino acid sequence given in first source; product of a functionally altered retinoic acid receptor alpha gene

Also Known As:

Networked: 265 relevant articles (23 outcomes, 17 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Chen, Zhu: 8 articles (02/2010 - 06/2000)
2.	Ley, Timothy J: 6 articles (02/2007 - 09/2003)
3.	Kogan, Scott C: 5 articles (12/2007 - 02/2003)
4.	Chen, Z: 5 articles (01/2007 - 01/2001)
5.	Gallagher, R E: 5 articles (04/2006 - 01/2000)
6.	Jing, Yongkui: 5 articles (09/2005 - 08/2002)
7.	Müller-Tidow, Carsten: 4 articles (06/2010 - 12/2004)
8.	de Thé, H: 4 articles (02/2009 - 06/2001)
9.	Zhu, J: 4 articles (09/2008 - 06/2001)
10.	Tenen, Daniel G: 4 articles (02/2008 - 02/2003)

Related Diseases

1.	Acute Promyelocytic Leukemia 12/01/2003 - "[Improved RT-PCR for detection of PML/RARalpha fusion gene in rapid diagnosis of acute promyelocytic leukemia]." 07/01/1996 - "Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia." 01/01/2001 - "Acute promyelocytic leukemia (APL) patients with t(15;17)(PML/RARalpha positive) achieve remission upon t-RA treatment, whereas patients with t(11;17)(PLZF/RARalpha positive) do not. " 07/01/2003 - "This study investigated the clinical characteristics and prognostic relevance of CD34 expression in 47 patients with acute promyelocytic leukemia (APL), showing t(15;17) or PML/RARalpha. " 05/01/2000 - "Identification of PML/RARalpha rearrangements in suspected acute promyelocytic leukemia using fluorescence in situ hybridization of bone marrow smears: a comparison with cytogenetics and RT-PCR in MRC ATRA trial patients. "
2.	Leukemia 08/01/2001 - "It is unclear whether ALLO-HSCT from an HLA-identical sibling is superior to AUTO-HSCT with PML-RARalpha-negative cells in CR2 since the former would be associated with graft-versus-leukemia effects and the latter with lower TRM. " 01/01/2004 - "Recent studies also showed that efficient induction of relevant human leukemia in mice by certain oncogenes, such as PML/RARalpha and TEL/ABL, only occurred when they were expressed at a low level or close to pathophysiologically relevant level. " 09/01/2010 - "In summary, our results indicate that ATO in conjunction with ATRA is of potential chemotherapeutic use in PML-RARalpha negative leukemias." 08/01/2009 - "PML-RARalpha initiates leukemia by conferring properties of self-renewal to committed promyelocytic progenitors." 12/01/2008 - "In contrast, the leukemia-associated fusion PML-RARalpha induced the degradation of HIPK2. "
3.	Neoplasms (Cancer) 03/01/2006 - "Other genes, which more recently emerged as regulators of cancer coagulopathy include: PML-RARalpha, PTEN, and MET. " 10/01/2004 - "In NB4 cells (expressing PML-RARalpha), this increase is transient and completely reversible, along with a cell cycle arrest, ongoing differentiation and lower sensitivity to anti-cancer-drug-induced apoptosis. " 11/23/2001 - "PML-RARalpha alleviates the transcriptional repression mediated by tumor suppressor Rb." 03/01/2001 - "Some recurrent aberrations and the resulting gene rearrangements, namely inv(16)/t(16;16) and CBFbeta- MYH11, t(8;21) and CBFA2-CBFA2T1, t(15;17) and PML-RARalpha, and rearrangements of band 11q23 and the MLL gene, are now used to help define distinct disease entities within AML in the new World Health Organization classification of haematological malignancies. " 11/21/2000 - "Interstitial or terminal deletions of the distal region of one copy of chromosome 2 [del(2)] were found in 1/5 tumors expressing PML-RARalpha, but in 11/13 tumors expressing both PML-RARalpha and RARalpha-PML (P < 0.05). "
4.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/01/2009 - "Within 14 acute myeloblastic leukemia patients, we confirmed 2 cases with FLT3-internal tandem duplication+, 1 patient with AML1-ETO, and only 1 case carrying a PML-RARalpha rearrangement. " 07/01/2008 - "Given that morphology of APL cases, as defined according to WHO criteria (95% of which carry the PML/RARalpha fusion gene), admits extremely divergent morphological pictures ofthe variant forms, we recommend these investigations to be performed in every case of de novo acute myeloid leukemia. " 02/01/2008 - "PML-RARalpha is the causative oncogene in 5% to 10% of the cases of acute myeloid leukemia. " 12/09/2004 - "Microarray analyses were performed to identify target genes that are shared by the acute myeloid leukemia (AML) translocation products PML-RARalpha, PLZF-RARalpha and AML1-ETO in inducibly transfected U937 cell lines. " 06/01/2000 - "We report on a case of acute myeloid leukemia with morphology, immunophenotype and clinical features typical of promyelocytic subtype (APL), in which the specific PML/RARalpha gene rearrangement was molecularly detected only at second relapse of disease, without cytogenetic evidence of the t(15;17). "
5.	Residual Neoplasm 11/01/2003 - "A total of 98 samples, comprising four groups, were evaluated: Group 1, 16 diagnostic samples molecularly positive by our existing laboratory-developed assays for PML-RARalpha/t (15;17) or BCR-ABL/t (9;22); Group 2, 51 diagnostic samples negative by our laboratory-developed assays for PML-RARalpha/t (15;17) or BCR-ABL/t (9;22); Group 3, 21 prospectively analyzed diagnostic cases, without prior molecular studies; and Group 4, 10 minimal residual disease (MRD) samples. " 01/01/2007 - "Longitudinal RT-PCR of PML/RARalpha allows sensitive assessment of response to treatment and minimal residual disease (MRD) monitoring in APL. " 03/01/2002 - "Acute promyelocytic leukaemia (APL) is characterized by the t(15;17)(q22;q21) leading to the formation of PML-RARalpha and RARalpha-PML fusion genes which provide suitable targets for the assessment of minimal residual disease (MRD). " 07/01/2001 - "Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive competitive RT-PCR method." 08/01/2000 - "Monitoring of minimal residual disease by RT-PCR of PML/RARalpha (sensitivity 10(-4)) showed negativity in 29 of 32 (91%) evaluable cases after induction, in 23 of 25 (92%) after consolidation, and in 27 of 30 (90%) during maintenance, after a median time of 2, 4 and of 18 months after diagnosis, respectively. "

Related Drugs and Biologics

1.	Tretinoin (Retinoic Acid)
2.	Proteins (Proteins, Gene)
3.	Arsenic Trioxide (Trisenox)
4.	Messenger RNA (mRNA)
5.	Retinoic Acid Receptor alpha
6.	Arsenic
7.	Aligeron (AS 2)
8.	Valproic Acid (Depakote)
9.	Oncogene Proteins (Oncogene Protein)
10.	RNA-Directed DNA Polymerase (Reverse Transcriptase)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Stem Cell Transplantation
4.	Maintenance Chemotherapy
5.	Salvage Therapy